ПРИМЕНЕНИЕ ЭВЕРОЛИМУСА ПРИ ТРАНСПЛАНТАЦИИ ПОЧЕК ОТ ДОНОРОВ С РАСШИРЕННЫМИ КРИТЕРИЯМИ


https://doi.org/10.15825/1995-1191-2009-4-103-109

Полный текст:


Аннотация

В статье приводятся данные об обосновании особых схем иммуносупрессии у пациентов, получивших почечный трансплантат от доноров с расширенными критериями. Особое внимание уделяется аспек- там снижения доз ингибиторов кальциневрина у пациентов старшей возрастной группы. Анализируются данные литературы об использовании иммуносупрессии с применением ингибиторов пролиферативного сигнала у пациентов, получивших субоптимальные трансплантаты почек. 


Об авторах

И. В. Ульянкина
ГУ «Санкт-Петербургский научно-исследовательский институт им. И.И. Джанелидзе», Санкт-Петербург
Россия


О. Н. Резник
ГУ «Санкт-Петербургский научно-исследовательский институт им. И.И. Джанелидзе», Санкт-Петербург
Россия


Я. Г. Мойсюк
ФГУ «Федеральный научный центр трансплантологии и искусственных органов им. академика В.И. Шумакова», Москва
Россия


Список литературы

1. Бикбов Б.Т., Томилина Н.А. О состоянии заместитель- ной терапии больных с хронической почечной недо- статочностью в Российской Федерации в 2005 г. // Нефрология и диализ. 2007. Т. 1. С. 6–85.

2. Мойсюк Я.Г., Милосердов И.А. Опыт применения Сертикана – нового ингибитора сигнала пролифе- рации при трансплантации органов // Нефрология и диализ. 2006. Т. 8. No 4. С. 336–343.

3. Abraham R.T., Wiederrecht G.J. Immunopharmacology of rapamycin // Ann. Rev. Immunol. 1996. Vol. 14. P. 483–490.

4. Arns W., Citterio F., Campistol J.M. «Old-for-old» – new strategies for renal transplantation // Neprol Dial Transplant. 2007. Vol. 22. P. 336–341.

5. Bradley B.A. Rejection and recipient age // Transpl. Immunol. 2002. Vol. 10. P. 125–130.

6. Bohler T., Waiser J., Budder K. et al. The in vivo effect of rapamycin derivative SDZ RAD on lymphocyte proliferation // Transplant. Proc. 1998. Vol. 30. P. 2195– 2198.

7. Canadian organ replacement register (CORR) // Annual Report. 2001.

8. Carter J.T., Chan S., Roberts J.P. Expanded criteria donor kidney allocation: marked decrease in cold ischemia and delayed graft function at a single center // Am. J. of Transplantation. 2005. Vol. 5. P. 2745–2753.

9. Cecka J.M. The OPTNUNOS renal transplant registry / J.M. Cecka, P.I. Terasaki (eds.) Clinical. Trasplant. 2003 // Los Angeles: UCLA Tissue Typing Laboratory. 2003.

10. Cohen B., Smits J.M., Haase B. et al. Expanding the donor pool to increase renal transplantation // Nephrol. Dial. Transpl. 2005. Vol. 20. P. 34–38.

11. Cornella C., Brustia M., Lazzarich E. Quality of life in renal transplant patients over 60 years of age // Transpl. Proc. 2008. Vol. 40. P. 1865–1866.

12. Dancey J.E. Inhibitors of the mammalian target of rapamycin // Expert Opin. Investig. Drugs. 2005. Vol. 14. No 3. P. 313–316.

13. Danovitch G.M., Savransky E. Challenges in the counseling and management of the older kidney transplant candidate // Am. J. Kidney Dis. In press.

14. Danovitch G.M., Gaston R.S. et. al. The report of a national conference on the wait list for kidney transplantation // Am. J. Transplant. 2003. Vol. 3. No 7. P. 775–785.

15. Danovitch G.M. A kidney for all ages // Am. J. Transplant. 2006. Vol. 6. P. 1267–1268.

16. DelmonicoF.L.,WynnJ.J.Managingtheenlargingwaiting list // Am. J. Transplant. 2002. Vol. 2. P. 889–890.

17. Eisen H., Dorent R., Manchini D. Safety and efficacy of everolimus as part of triple immunosuppressive regimenin de novo cardiac transplant recipient: six month analysis // J. Hearth. Lung. Tansplant. 2002. Vol. 21. P. 55–57.

18. Fellstrom B. Cyclosporine nephrotoxicity // Transpl. Proc. 2004. Vol. 36. P. 220s–223s.

19. Feutren G., Mihatsch M.J. Risk factors for cyclosporine- induced nephropathy in patients with autoimmune diseases. International Kidney Biopsy Registry of cyclosporine in Autoimmune Diseases // N. Engl. J. Med. 1992. Vol. 326. P. 1654–1657.

20. Giron F., Baez Y., Nino-Murcia A. et al. Conversion therapy to everolimus in renal transplant recipients:results after one year // Transpl. Proc. 2008. Vol. 40.

21. P. 711–713.

22. Hariharan S., Jonson S.P., Bresnahan B.A. Improved

23. graft survival after renal transplantation in the Unated States, 1988 to 1996 // N. Engl. J. Med. 2000. Vol. 342. P. 605–612.

24. Holdaas H., Bentdal O., Pfeffer P. et al. Early, abrupt conversion of de novo renal transplant patirts from cyclosporine to everolimus: results of a pilot study // Clin. Transplant. 2008. Vol. 22. P. 366–371.

25. Hussar D.A. New drugs in 1999 // J. Am. Pharmaceut. Soc. 2000. Vol. 40. P. 181–184.

26. Krieger N.R., Becker B.N., Heisey D.M. et al. Chronic allograft nephropathy uniformly affects recipients of cadaveric, nonidentical living-related and living-unrelated graft // Transplantation. 2003. Vol. 75. P. 1677–1683.

27. Li Y.T, Danguilan R.A., Cabanayan-Casasola C.B. et al. Everolimus with reduced-dose cyclosporine in de novo renal transplant recipients: philippine experience // Transpl. Proc. 2008. Vol. 40. P. 2211–2213.

28. Luke P.P.W., Nguan C.Y., Horovitz D. Immunosupression without calcineurin inhibition: optimization of renal function in expanded criteria donor renal transplantation // Clin. Transplant. 2008. Vol. 10. P. 1–7.

29. Majevski M., Korecka M., Kossev P. et al. The immu- nosuppressive macrolide RAD inhibits growth of the human Epstein-Barr virus-transformed B-lymphocites in vitro and in vivo: a potential approach to prevention and treatment of posttransplant lymphoproliferative disorders // Proc. Natl. Acad. Sci. 2000. Vol. 97. P. 4285– 4291.

30. Martins P.N.A., Pratschke J., Pascher A. et al. Age and immune response in organ transplantation // Transplanta- tion. 2005. Vol. 79. P. 127–132.

31. Matas A.J., Lawson W., McHugh L. et al. Employment patterns after successful kidney transplantation // Transplantation. 1996. Vol. 61. P. 729–733.

32. Meier-Kriesche H., Schold J.D., Gaston R.S. et al. Kidneys from deceased donors: maximizing the value of a scarce resource // Am. J. Transplant. 2005. Vol. 5. P. 1725–1730.

33. Montagnino G., Sandrini S., Casciani C. A randomized trial of steroid avoidance in renal transplant patients treated with everolimus and cyclosporine // Transpl. Proc. 2005. Vol. 37. P. 788–790.

34. Moro J., Almenar L., Martinez-Dolz L. mTOR inhibitors: Do they help preserve renal function? // Transpl. Procs. 2007. Vol. 39. P. 2135–2137.

35. Nankivell B.J., Borrows R.J., Fung C.L. et al. The natural history of chronic allograft nephropathy // N. Engl. J. Med. 2003. Vol. 349. P. 2326–2331.

36. Nashan B. The role of Certican in the many pathways of chronic rejection // Transplant. Proc. 2001. Vol. 33. P. 3215–3219.

37. Nicholson M.J. Renal transplantation from non-heart- beating donors: Opportunities and Challenges // Transpl. Reviews. 2000. Vol. 14. No 1. P. 1–17.

38. Ojo A.O., Hanson J.A., Meier-Krieshe U. Survival in recip- ients of marginal cadaveric donor kidneys compared with other recipients and wait listed transplant candidates // J. Am. Soc. Nephrol. 2001. Vol. 12. P. 589–597.

39. Pascual J., Ioannis N.B., Campistolc J.M. et al. Evero- limus (Certican) in renal transplantation: a review of clinical trial data, current usage and future directions // Transpl. Reviews. 2006. Vol. 20. P. 1–12.

40. Pascual M., Theruvath T., Kawai T. et al. Strategies to improve long-term outcomes after renal transplantations // N. Engl. J. Med. 2002. Vol. 346. P. 580–585.

41. Pohanka E. Conversion to everolimus in maintenance patients – current clinical strategies // Nephrol Dial Transplant. 2006. Vol. 21. Р. 24–29.

42. Ponticelli C. Can mTOR inhibitors reduce the risk of late kidney allograft failure? // Transplant. International. 2008. Vol. 21. P. 2–10.

43. Ponticelli C. The pleiotropic effects of mTOR inhibitors // J. Nephrol. 2004. Vol. 17. P. 762–768.

44. PortF.Expandedcriteriadonorsforkidneytransplantation // Am. J. Transpl. 2003. Vol. 3. No l4. P. 114–125.

45. Ruiz J.C., Sanchez-Fructuoso A., Rodrigo E. et al. Conversion to everolimus in kidney transplant recipients: a safe and simple procedure // Transpl. Proc. 2006. Vol. 38. P. 2424–2426.

46. Schena F.P. Review of symposium // Transpl. 2009. No 87 (Suppl. 8). P. 30–33.

47. Schmidbauher G., Hancock W., Wascouska B. et al. Abrogation by rapamycine of accelerated rejection in sensitized rats by inhibition of alloantibody responses and selective suppression of intragraft mononuclear and endothelial cells activation, cytokine production and cell adhesion // Transpl. 1998. Vol. 57. P. 933–937.

48. Schuler W., Sedrani R., Cottens S. et al. SDZ RAD, a new rapamycin derivative. Pharmacological properties in vitro and in vivo // Transpl. 1997. Vol. 64. P. 36–39.

49. Sung R.S., Guidinger M.K., Lake C.D. Impact of the ex- panded criteria donor allocation system on the use of ex- panded criteria donor kidneys // Transpl. 2005. Vol. 79. No 9. P. 1257–1261.

50. Viella –Bach M. Nuzzi P., Fang Y. et al. The FKBP12- rapamycin binding domain ia required for FKBP12- rapamycinassociated protein kinase activity and G1 progression // J. Biol. Chem. 1999. Vol. 274. P. 4266– 4269.

51. Vitko S., Tedesco H., Eris J. et al. Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies // Am. J. Transplant. 2004. Vol. 4. P. 626–629.

52. Wavamunno M.D., Chapman J.R. Individualization of im- munosupression: concepts and rationale // Current Opinion in Organ Transplantation. 2008. Vol. 13. P. 604–608.

53. Wolfe R.A., Ashby V.B., Milford E.L. et al. Comparison of mortality in all patients on dialisys, patients on dialisys wai- ting transplantation and recipients of a first cadaveric trans- plant // N. Engl. J. Med. 1999. Vol. 341. P. 1725–1729.


Дополнительные файлы

Для цитирования: Ульянкина И.В., Резник О.Н., Мойсюк Я.Г. ПРИМЕНЕНИЕ ЭВЕРОЛИМУСА ПРИ ТРАНСПЛАНТАЦИИ ПОЧЕК ОТ ДОНОРОВ С РАСШИРЕННЫМИ КРИТЕРИЯМИ. Вестник трансплантологии и искусственных органов. 2009;11(4):103-109. https://doi.org/10.15825/1995-1191-2009-4-103-109

For citation: Ulyankina I.V., Reznik O.N., Moysyuk Y.G. THE USE OF EVEROLIMUS IN KIDNEY TRANSPLANTATION FROM EXPANDED CRITERIA DONORS. Russian Journal of Transplantology and Artificial Organs. 2009;11(4):103-109. (In Russ.) https://doi.org/10.15825/1995-1191-2009-4-103-109

Просмотров: 275


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1995-1191 (Print)
ISSN 2412-6160 (Online)